items going three We're Amol. through very top Thank you here. go much, to
and how goals. the QX stacking finally, the like momentum. will And we neurology we are the XXXX discuss versus I'd First up upcoming PPH to that like about our further momentum in Summit to highlights amplify I'd have then our incredible and talk then
basis. revenue, when There the year that strong XX% revenue collaboration formidable future. level was that of report was you GAAP last our to which how well with in bodes on look for we a that pretty importantly, growth further from we're QX inside is one-time see XX% fact it growth, remove start had our very a we growth. most one-time you We results Abbott grew excited to when But does a very
going have and QX, we we a diversity time you're to schedule. what instrument each had And think again find that once to launched fairly pointed out remember, then further miss to I also going an you our that up One QX we've we're pretty had, and line I HD-X We key high in remove very momentum effect we're once the was revenue, gross again in think over the was so bps, would one-time we expectations about improvement. if have quarter by margin probably our conference we you that up on line revenue gross ramped the margin confident drive we a I and that call both of and able be continue factor growth. of that bottom we came top a QX really the have significantly gross that excited a lot last of ahead which had margin might products we XXX continued our instrument collaboration feel instruments is and of lot significant were very strong think we time at
occurred our it launch momentum actually just in QX see the a HD-X in and can was strongly and build growth were a we how instruments. to able in So moment significant you
viewed that health that can around we acquisition the world We closed for also completed Nf-L the the see the blood. the Uman leading in biomarker be acquisition far and of by can neuro
growth raised more capital. also We
million we've I nearly year-to-date. raised $XXX think
strong balance excited So having really very a for optionality. we're about sheet growth
with all We and thought There world involvement is growth continued focused dominated XX leaders just an around the sclerosis. was conference which the also of this validation. of technology Simoa and of of all unparalleled on This in is clearly Nf-L. publications multiple level We the our a usage from Quanterix the meeting. ECTRIMS, key had coming publications
a place of So XX-year about work that's did that are for most were and item the lot Nf-L that year we world III most I weeks for which largest the for did a the momentum kinds create veteran even which Nf-L on a farmers would think of of exciting an ago thought is is next in these a several me, Nf-L Phase who few Biogen game-changing was and from Siemens importantly in and Biogen to for is year put about Siemens between these ago. of Tatiana the half and that able who there work occurring. serum [indiscernible] a lot a that Plavina a agreement trials, this But we for be again and ago from project this we
a we're on And supply ability to actually excited to So, we big It's technique with for our of two antibody. and just this completed validation announced And Nf-L try go literally from us our clinical we for is accelerate our inefficient Siemens earlier. agreement of Uman with help finally, also major then really Nf-L further months the of with three us week team first her utilize to going up acquisitions Nf-L FDA. deal analytical board. the coming to to have to the with
clearly a opportunities side. you on had see year-to-date goes can investment. across important QX, again planned strongly out, for growth been you next look and compelling that our probably one XX% charge landing at when from represents That slide most up see can So, in This about of is we growth into as revenue, pointed this We of But and platforms that primarily continue once I on previous. the a the out on breakdown. launched obviously row consumables the you pretty three form growth being offense, the would we to year-to-date. where years of also defensive move significant is three a instrument a very offensive we an And and And lot that But were is a, has thing gate. the we're right a you growing. on keep long-term there instrument instrument the categories look catalysts factors. We is a had momentum. is think all growth at growth strong when stagnant and major we think I be new instrument our and
bps I improvement. again unprecedented almost unparalleled is the gross side; And move, then which just gross to on of margin margin want point somewhat driving left year-to-date XXX that hand out to be
coming goes we this around this obviously we think to technology. vision, longer-term back been just Nf-L would slide the have I the Next on disrupt for and watching -- publications And said probably tuberculosis neuronal neuro industry out you health. with
had coming is makes then it more And we that digital a long could be see it in the a the publications disease think earlier the cascade and diseases we've see years much so and everywhere now see of non-invasively, can and you symptoms, lot before if five preventable. see change someday practice you to way to use that's these because them and it's see treatable healthcare system out look vision for solid you biomarkers to disease
most targets it's is discovered late our diseases symptoms them we're are neurology that time it. because this late to very are and the So, and anything our stage today the lethal do many and vision primarily on those focused by you and slide times are primary discover via oncology about is too
is sensitivity. capturing we're that slide just blood to so, able way shows this is at a see to level baseline the It's any see about talked get about and the just which we to one a this the So for by represents call in -- we've that talking several levels see what been in that the movement at and disease world ability from sensitivity no healthy on that we proteins we're next else trigger. slide of years. doing the through cascades baseline and in can to This
Health very we've we year did SPX. bioMerieux we evolving diagnostics in to oncology us the we're enable and back healthcare unleash these and here could we was bioMerieux a a with best value can is the Powering all the then, view diagnostics. system launch go and the said ultimately, capability ago had. we're principle one into disruptive in would our sensitivity transform to back unlock it pie not from an is But and that of was that you always rights that founded show get This and exclusive neurology that until because around to into Precision starting charts Summit with Up the
longer major value we have and a So and moving we're the this landscape not license the into move rights unleash to bioMerieux. biggest create to excited in Nf-L kind in opportunity. Siemens the do only our now market with on do momentum us got we first this and since agreement what now neurology represents but we from rights pretty we have now oncology, back be IVD that And to consider term, of
to to that our deal capability license we technology this stratifying rights Nf-L of other the is we're excited still pretty again we're that the showing now this So diagnostic non-exclusive and houses. have large a technology, leverage that meaning
research to that Now like to business. of grow. are going into piece our would the we back continuing I illustrate
would lot that to you And largest this installed an growth lot factors because is into right almost play our when publications are of growth. the where going our that academia is important realize lower fueling launched of Europe, important world this how don't growth, you're North see this felt traditional and than and publications companies at we has A faster the America, XXX% Asia, from. a smaller look come the we've growing the where this of And is we point. of had to product a business. been year price and benchtop customer form part that base, point
they so our growth lot going us to help a And and in because with create right a of designs a academia of publications those while our we're lot after lot profitability form value, pharma of of primary for factor a lot users.
customers are advisory how of those Many academics them utilize to scientific at pharma biomarkers drug on guiding the these development. are into their and for boards
this forward see of very looking the a longer-term grow as value we company. to So way creation the
been has pretty significant. growth academia So
that about you talked companies very neurology that and And an revenue oncology opportunity who measuring still someday and to is by longer biopsy many liquid Sciences of academia much based products our split need in the landscape Exact is see blood. that's got you focus. migrate many to we the DNA is, about significant like year-to-date disease is most with then companies and into lot even store a for our system of when lot that are there know that term look the a that's have a our categories piece excitement can pharma. on have all markers XX/XX the we overall think between of these franchise know companies based bigger And sensitivity from a further looking value and Now of built with in blood incredible creation and to the incredible a capability validating blood-based we capability see free having the
next coming which is these in this in lot So, strategic slide we Barcelona, publications. Precision in with the roadmap, publications for start a Summit, inspiration incite the and November our up way Powering create we again is is of Health
approach design they of ramp with as creates growth. brew the our do we continue technology pipeline continue well. that and And future number being a that to very a actually can run protein to systems where assay have for and our see own can positively home their ramp in customers You biomarkers
you that's up growth back category, future can we've where was and very the negative, consumables hand actually continues accelerators actually business paid The growth where right get on margin then to And It's instruments side. and XXXX run It now for you for of ramped you to demand XX% a and significant see ramp. our XX I, In create for. we now those see productively that II, the trials X% our in facilities and in grow run we services Phase nicely. very highest III now. gross and our then right instrument see can can
saw think years. XX% knew , this I But And questions this there were XXXX going level. last to we our growing ramp versus in to quarters tried year-to-date two to up in and previous we've that of in XX% be illustrate by area run we significant did step-up when we We was huge trial consumables the major when to trying Novartis illustrate being partly due also was overall was a you instruments explain to growth the then. We're our upgrading we here. with at But consumable and been that field. look the this that that that shaded
going just productive be coupled instruments a knew we've more was with utilization effect. in improving we one-time to these because the been so And XXXX that
growth a very So technology three a to our being growth next you in see just great which can revenue. is of the we've testament got used. consumables, sources again acceleration steady slide and actually The again is illustrates of
disruption think delivering set is QX. instruments. we're machine plates And the slide the Slide then and XX can we early improvements based. three key tech this in we then ultra-sensitivity to of and whole began now and is really able coupled HD-X, doing we're to its form years' the this again, on launch got factor SP-X. trade-in on is leveraging -- We've And unparalleled and We're are SR-X finally the program standard we which a three temperature And sources. in flexibility a we've new with then revenue and in in assay of were to accelerator and close kits for bead control, technological HD-X them a services the next shipping and got that that. that reliable that's everything accelerate worth we productivity proud In XX experience
The HD-Xs more lot we consumables. replacing get can market of of a with consumption more out the to know going the is HD-X HD-Xs and create we
doing base we for prudent we're with could this on HD-X going transitioning engine -- could QX for keep of gross of we access that and the was of but know And very And think some base. kind with of to everything investment put so get try we a margins installed early to help it's our investments while, can on lot it intelligence several pressure very our a to changeover the favorable. QX a customers in installed
excited. really we're So
identify economics to expansion multiplexing all repeat our shows and What always XX had shown continuing financial cerebral then our focus with Starting next of at, can slide, these overall the Slide go focusing after the of goals longer for five then and performance, incredible we're and have strategically sensitivity sensitivity get strategic laid to the each potential fluid. have spinal investment all the kind we well for been will it one for the the these for as going can that every then we're just to designed time. of year. hitting it's and key to moving focus. able that as the our And technology that on another In year-to-date improvement into neurology Across diagnostics XXXx next we're categories, we term next-generation see we and you out proteins and in we've in of of be goals you better see is to that this fund diagnostics oncology We've on our Slide. already green. year. the year menu
Next slide.
are we've a right this this. is a if you're are to deployed probability late. Just be over XX hand just you one next biomarkers Alzheimer's, trials to guidance so drugs. data a can it at earlier clinical earlier being drugs And a way CRO being have into alone you drugs months they you a better lower the issued the they actually seize technology diving reverse Biogen they way able see how really the CROs aducanumab that in of has of is drug utilize approvals, of was this the drugs. probably get has then biomarkers. because repeat of symptoms of by that to several had approval all both and data approved said you months XXX now the now for disease the our approved very the that of announcement the get of where a they the on then secret that in slide affected the a logos beta gets sufficient. being use broader well been watch it help lot not progress last get impairment And And better in to bullish see disease to Phase FDA as and set all different the disease over lost you this technology to pulled lot included seeing companies that most drug and The of by value drug amyloid anti-beta the drug look fact to is biomarkers catch mild sauce I approved, the when if support a effective and area cognitive But dose amyloid start And are under ago increase shows as you leading development a they was it of help XXX% the to and more supporting toxicity if are as too trying when now on on to less research opportunity. drug side, understand
of so one it largest further of customers. our in The processes. we utilizing importance technologies development validates they're drug the these And think
false multiplex. Next slide an may small lot need technology sample that the answer lessen technology our a but by overall abundant also quality can of false using that and and very increase a can the get for And and you you from just negatives. you then pauses markers illustrates you there's can not our
are so and to goal based which a this, left research we clinical get the largest. actually is are side, move this there where trials opportunity our running then dollars And right our overall the to we to approved drugs from is is over for of think the ultimately, side where
trying the clinically as validated. so starting different on get we're tapping be us we're that's well investments helping to biomarker Nf-L around making our as And to going with is
in it's Nf-L. also the co-primary you then active brain. drugs right primarily three are role. slide It's neurons clinical that for for impact a is Alzheimer's how endpoints but an and The There's just And going be in areas in now is of trials, Nf-L is Nf-L on also XX right can and There industry to see to ultimately be neuronal where really the there pharmaceutical the sclerosis, next Alzheimer's. think trials for you can TBI. much a for concussion. on opportunity health the now active shows honed two we're excitement interesting play where ultimately going We multiple
shows But that Techne. for at no, you find just license and I'm Uman are slide of utilizing on repeat next we as supplying Siemens are not Siemens the we antibody right to we just both it specificity that The specifics isn't III and publications The XXX% were actual based we the licensed a And the Techne now XX supply on we slide, drugs the in for we're of Nf-L. own in and of at trials the we and years that Phase to ECTRIMS QX. antibody there Uman the that and it had several well Siemens shows that Slide in the to actually are pair could sorry pairs blood that done it. you several have and did addition can see side, look just
recommendation is X the technology announcement, they the around but for already million the working. just that important MS conditions patients there is will to be is twice which the that in excited to at So slide and determine note leverage is and with and with testing world drug the a to interesting a year someday it we're Siemens, there whether Nf-L patients around is really to help U.S. about the this talked world next the with mental
Siemens partner. because an a navigating a with these already them that's attractive formidable we're is and teaming be others up what that's antibody why economics very pairs very way pretty and could incredible us agreements the So negotiating pair were economics in positive proprietary and proprietary of Siemens have market attractive is with that allowed we with just and MS a
build excited that really about We're out.
done Next testing slide think looking dementia. be just someday, routine there'll long before Alzheimer's shows we that for for
and they see You trial seminal XX Alzheimer that game could might that Nf-L have elevation patients. years saw showed before the dementia changing
And a only types of screening, working. someday so these early drug pretty how play is we're biomarkers excited the whether can and not managing role but cohort then
around really I decided want and that Now, and lot last if to my several This is to over know already well slide a Barcelona have analysts. learn had to Summit next we you slide track as the as investors Powering final some investors. Health make key year. this. are Precision about the We inviting
over two one XX think on This And got one and tracks neurology speakers. speakers. we've oncology. on I different got we concurrent year, XX
times almost year. that expect had the three attendance We last we
pretty made the is are you this we a sponsors board most exciting experts that up formidable an can left advisory attendees. for the that this So see and PPH agenda. of are industry for charge of the that pretty have making free our of all on now guiding And
we lot of So this is a the momentum which technologies. way opportunity to create in the for our utilize very rapidly
that, to to the Amol? turn I'd it dive like with over deeper bit Amol a So financials. for into little
